Kronenberg Florian, Lhotta Karl, König Paul, Margreiter Raimund, Dieplinger Hans, Utermann Gerd
Institute of Medical Biology and Human Genetics, University of Innsbruck, Schöpfstrasse 41, A-6020 Innsbruck, Austria.
Eur J Hum Genet. 2003 Sep;11(9):693-9. doi: 10.1038/sj.ejhg.5201016.
The atherogenic lipoprotein(a) (Lp(a)) is significantly increased in patients with kidney disease. Some studies in hemodialysis patients described this increase to be dependent on the genetic apolipoprotein(a) (apo(a)) isoforms. Only patients who express high molecular weight (HMW) apo(a) isoforms but not those with low molecular weight (LMW) isoforms show a relative increase of Lp(a) when compared to healthy controls matched for apo(a) isoforms. However, this was not confirmed by all studies. We therefore prospectively investigated the changes of Lp(a) deriving from each apo(a) isoform in heterozygotes following kidney transplantation. Lp(a) concentrations were measured by ELISA. To calculate the isoform-specific concentrations and the changes of Lp(a) deriving from each isoform, we densitometrically scanned the apo(a) bands from immunoblots before and after transplantation in 20 patients expressing two apo(a) isoforms. Of these, 10 patients expressed both an LMW and an HMW apo(a) isoform. The other 10 patients expressed only HMW isoforms. Densitometric scanning of apo(a) bands and calculation of isoform-derived Lp(a) concentrations clearly demonstrated that the decrease of Lp(a) following kidney transplantation is caused by changes in the expression of HMW apo(a) isoforms. In some patients, we observed an almost complete disappearance of the HMW apo(a) isoform after transplantation. This study clearly demonstrates that the changes of Lp(a) plasma concentrations in kidney disease depend on the genetically determined size of apo(a). This provides evidence for an interaction of apo(a) genetic variability and kidney function on Lp(a) concentrations.
致动脉粥样硬化性脂蛋白(a)(Lp(a))在肾病患者中显著升高。一些针对血液透析患者的研究表明,这种升高取决于遗传载脂蛋白(a)(apo(a))异构体。与匹配apo(a)异构体的健康对照相比,只有表达高分子量(HMW)apo(a)异构体的患者,而非低分子量(LMW)异构体的患者,Lp(a)会相对升高。然而,并非所有研究都证实了这一点。因此,我们前瞻性地研究了肾移植后杂合子中源自每种apo(a)异构体的Lp(a)变化。通过酶联免疫吸附测定法(ELISA)测量Lp(a)浓度。为了计算异构体特异性浓度以及源自每种异构体的Lp(a)变化,我们对20名表达两种apo(a)异构体的患者移植前后免疫印迹中的apo(a)条带进行了光密度扫描。其中,10名患者同时表达LMW和HMW apo(a)异构体。另外10名患者仅表达HMW异构体。对apo(a)条带的光密度扫描以及异构体衍生的Lp(a)浓度计算清楚地表明,肾移植后Lp(a)的降低是由HMW apo(a)异构体表达变化引起的。在一些患者中,我们观察到移植后HMW apo(a)异构体几乎完全消失。这项研究清楚地表明,肾病中Lp(a)血浆浓度的变化取决于apo(a)的基因决定大小。这为apo(a)基因变异性与肾功能对Lp(a)浓度的相互作用提供了证据。